| Company Name: | Dyadic International, Incorporated | | Ticker Symbol: | DIL | | | WWW Address: | www.dyadic-group.com | | CEO: | Mark A. Emalfarb | | No. of Employees: | 125 | | Common Issue Type: | CS | | Business Description: | The Company is a biotechnology company engaged in the development, manufacture and sale of enzymes, other proteins, peptides and other bio-molecules derived from genes, and the collaborative licensing of its enabling proprietary technologies.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | |  | - | - | 0 | 5.30 | 5.30 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 158.7 | 29.9 | 0.51 | -0.45 | 0.00 | 0.0 | 0.0 | 7.10 - 3.65 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 5.30 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 158.7 | mil |
| Latest Shares Outstanding | 29.9 | mil |
| Earnings pS (EPS) | -0.45 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 123,070 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 19.1 | mil |
| Float as % of Shares Outstanding | 63.7 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 68.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 27.50 | % |
| Gross Profit Margin | 30.3 | % |
| EBITDA Margin | -65.9 | % |
| Pre-Tax Profit Margin | -70.2 | % |
| Assets Turnover | 0.4 | % |
| Return on Assets (ROA) | -24.1 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -35.6 | % |
| Current Ratio | 9.3 | |
| Leverage Ratio (Assets/Equity) | 1.6 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.09 | |
| LT Debt/Total Capital | 8.0 | % |
| Working Capital pS | 1.22 | $ |
| Cash pS | 1.04 | $ |
| Book-Value pS | 0.94 | $ |
| Tangible Book-Value pS | 0.88 | $ |
| Cash Flow pS | -0.34 | $ |
| Free Cash Flow pS | 0.01 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 5.64 | |
| Price/Tangible Book Ratio | 6.02 | |
| Price/Cash Flow | -15.6 | |
| Price/Free Cash Flow | 530.0 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 99 | 0 | 0 |
| 4 Weeks | 0.00 | 0.00 | 5.30 | 0.0 | 99 | 0 | 0 |
| 13 Weeks | 6.02 | 5.25 | 5.61 | -5.5 | 89 | 66 | 4,085 |
| 26 Weeks | 6.96 | 4.88 | 4.89 | 8.4 | 100 | 537 | 66,620 |
| 52 Weeks | 7.10 | 3.65 | 5.76 | -8.0 | 73 | 641 | 159,486 |
| YTD | 6.96 | 4.65 | - | -13.1 | 80 | 573 | 75,615 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 5.30 | 5.30 | 5.30 | 5.68 | 5.47 | 0.51 | 0.46 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 0.00 | NA | 0.00 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -3.1 | -15.8 | -3.1 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.03 | 0.00 | 0.03 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 81.22 |
| Current Ratio | 9.3 |
| Quick Ratio (Acid Test) | 7.7 |
| Liquidity Ratio (Cash) | 7.04 |
| Receivables Turnover | 5.4 |
| Average Collection Period | 67 |
| Working Capital/Equity | 130.1 |
| Working Capital pS | 1.23 |
| Cash-Flow pS | -0.34 |
| Free Cash-Flow pS | 0.01 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 5.81 |
| Financial Leverage Ratio (Assets/Equity) | 1.6 |
| Debt Ratio | 37.5 |
| Total Debt/Equity (Gearing Ratio) | 0.09 |
| LT Debt/Equity | 0.08 |
| LT Debt/Capital Invested | 41.0 |
| LT Debt/Total Liabilities | 14.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 1.46 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.96 |
| Tobin's Q Ratio | 3.52 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -14.26 |
| Enterprise Value (EV)/Free Cash Flow | 527.56 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 6.02 |
| Price/Book Ratio - LTM | 5.64 |
| Price/Cash Flow Ratio | -15.6 |
| Price/Free Cash Flow Ratio - LTM | 530.0 |
| Price/Sales Ratio | 10.39 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.08 |
| Current Liabilities pS | 0.15 |
| Tangible Book Value pS - LTM | 0.88 |
| Book Value pS - LTM | 0.94 |
| Capital Invested pS | 1.02 |
| Cash pS - LTM | 1.04 |
| Cash Flow pS - LTM | -0.34 |
| Free Cash Flow pS - LTM | 0.01 |
| Earnings pS (EPS) | -0.45 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 1.76 |
| Free Cash Flow Margin 5YEAR AVG | -36.70 |
| Net Profit Margin | -70.7 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.55 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.50 |
| Return on Capital Invested (ROCI) | -35.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.0 |
| Assets Productivity | 0.40 |
| Return on Assets (ROA) | -24.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.0 |
| Gross Profit Margin | 30.3 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | -65.9 |
| EBIT Margin - LTM | -66.4 |
| Pre-Tax Profit Margin | -70.2 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | -0.6 |
| Effective Tax Rate - 5YEAR AVRG. | -0.3 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 257 |
| Revenue per Employee | 123,070 |
| Net Income per Employee | -87,058 |
| Average Collection Period | 65 |
| Receivables Turnover | 5.4 |
| Day's Inventory Turnover Ratio | 192 |
| Inventory Turnover | 1.9 |
| Inventory/Sales | 39.3 |
| Accounts Payble/Sales | 15.79 |
| Assets/Revenue | 2.50 |
| Net Working Capital Turnover | 0.42 |
| Fixed Assets Turnover | 3.78 |
| Total Assets Turnover | 0.4 |
| Revenue per $ Cash | 0.50 |
| Revenue per $ Plant | 8.48 |
| Revenue per $ Common Equity | 0.55 |
| Revenue per $ Capital Invested | 0.50 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 68.7 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 27.5 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 27.5 |
|
|  
|
| |
 |  |